Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAA ABOUSAIF

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1235124108
CMS profile
9921
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$36,155.95

247 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAA ABOUSAIF

NPI 1235124108 · CMS profile ID 9921

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235124108?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235124108?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235124108?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALAA ABOUSAIF, NPI 1235124108, CMS profile ID 9921, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235124108?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

247 matching records · $36,155.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 247 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 247.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $1.5911/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459675 CMS
Phathom Pharmaceuticals, Inc. $1,200.0011/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151031954 CMS
ABBVIE INC. $34.0811/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167756 CMS
Celltrion USA Inc. $14,186.8310/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075847713 CMS
Janssen Biotech, Inc. $21.2710/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315504 CMS
Madrigal Pharmaceuticals $41.0010/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144159383 CMS
AIMMUNE THERAPEUTICS, INC. $20.9410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146991620 CMS
Ipsen Biopharmaceuticals, Inc $150.0010/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091978912 CMS
QOL Medical, LLC $15.1110/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147716099 CMS
Ferring Pharmaceuticals Inc. $17.2410/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459967 CMS
Gilead Sciences, Inc. $25.6810/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133791969 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.4010/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153660842 CMS
ABBVIE INC. $18.0510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167752 CMS
ABBVIE INC. $30.9910/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167754 CMS
VIVUS LLC $15.3710/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129414390 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9710/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459663 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.9010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459666 CMS
ABBVIE INC. $3.8610/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167750 CMS
Madrigal Pharmaceuticals $39.2110/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144159381 CMS
AIMMUNE THERAPEUTICS, INC. $16.2110/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146992279 CMS
AIMMUNE THERAPEUTICS, INC. $16.2110/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146997068 CMS
Celltrion USA Inc. $31.5410/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075847711 CMS
PFIZER INC. $9.3410/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131980003 CMS
ABBVIE INC. $13.4310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167748 CMS
Ardelyx, Inc. $29.5410/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146666671 CMS
Gilead Sciences, Inc. $15.2210/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133791967 CMS
Phathom Pharmaceuticals, Inc. $19.4510/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151031952 CMS
ABBVIE INC. $31.3610/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167746 CMS
Celltrion USA Inc. $20.5810/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075847709 CMS
Janssen Biotech, Inc. $119.7610/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315450 CMS
Phathom Pharmaceuticals, Inc. $2,400.0010/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151031950 CMS
QOL Medical, LLC $14.2510/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147716097 CMS
AIMMUNE THERAPEUTICS, INC. $22.0810/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147012978 CMS
Janssen Biotech, Inc. $27.5810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078315192 CMS
Celgene Corporation $20.1009/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101177302 CMS
Phathom Pharmaceuticals, Inc. $126.4509/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151031948 CMS
ALBIREO PHARMA, INC. $22.1409/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1071127158 CMS
ABBVIE INC. $32.0809/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167744 CMS
Exact Sciences Corporation $26.3509/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114568354 CMS
Madrigal Pharmaceuticals $35.8309/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144159379 CMS
Ferring Pharmaceuticals Inc. $21.7709/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459963 CMS
ABBVIE INC. $12.5909/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167742 CMS
Celltrion USA Inc. $6.7009/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075847707 CMS
QOL Medical, LLC $30.5809/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147716095 CMS
Ardelyx, Inc. $28.9609/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146666669 CMS
AIMMUNE THERAPEUTICS, INC. $11.6509/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147012900 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.6609/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153498431 CMS
Phathom Pharmaceuticals, Inc. $23.0509/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151031946 CMS
ABBVIE INC. $33.1509/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167740 CMS
ABBVIE INC. $5.1509/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103167738 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,232.68 134
PY2020 $4,064.78 69
PY2021 $4,217.03 160
PY2022 $3,452.00 203
PY2023 $3,404.95 186
PY2024 $36,155.95 247
PY2025 $13,201.50 251

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $934.02 1
PY2025 Principal investigator $275,142.00 70
PY2024 Principal investigator $895,988.87 155
PY2023 Principal investigator $541,023.60 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Eli Lilly and Company $934.02 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872061
Principal investigator 1 Madrigal Pharmaceuticals $2,430.08 11/25/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.00 11/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263789
Principal investigator 1 Madrigal Pharmaceuticals $2,010.06 11/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,043.00 10/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184252698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184252700
Principal investigator 1 Madrigal Pharmaceuticals $2,010.06 09/23/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250558
Principal investigator 1 Madrigal Pharmaceuticals $9,075.38 09/18/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250229
Principal investigator 1 Madrigal Pharmaceuticals $150.00 09/18/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250233
Principal investigator 1 Genentech, Inc. $7,224.00 08/27/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620122
Principal investigator 1 Madrigal Pharmaceuticals $4,020.12 08/21/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248871
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 08/20/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763741
Principal investigator 1 Genentech, Inc. $7,342.00 08/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620112
Principal investigator 1 Genentech, Inc. $2,736.00 08/20/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620117
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 08/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248424
Principal investigator 1 Madrigal Pharmaceuticals $5,600.88 08/14/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248429
Principal investigator 1 Boehringer Ingelheim International GmbH $1,762.60 07/31/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763739
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247761
Principal investigator 1 Madrigal Pharmaceuticals $750.00 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247765
Principal investigator 1 Madrigal Pharmaceuticals $1,837.05 07/31/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247769
Principal investigator 1 Bausch Health US, LLC $1,358.00 07/23/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,391.40 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,244.20 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,350.00 07/17/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184217200
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763733
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763735
Principal investigator 1 Boehringer Ingelheim International GmbH $12,500.00 07/16/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763737
Principal investigator 1 Madrigal Pharmaceuticals $9,668.70 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246813
Principal investigator 1 Madrigal Pharmaceuticals $11,505.38 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246818
Principal investigator 1 Madrigal Pharmaceuticals $200.00 07/10/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246822
Principal investigator 1 Madrigal Pharmaceuticals $15,150.38 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245978
Principal investigator 1 Madrigal Pharmaceuticals $300.00 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245982
Principal investigator 1 Madrigal Pharmaceuticals $3,674.10 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245986
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 06/24/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245989
Principal investigator 1 Bausch Health US, LLC $377.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842388
Principal investigator 1 Bausch Health US, LLC $1,686.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842391
Principal investigator 1 Bausch Health US, LLC $2,111.00 06/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842399
Principal investigator 1 Madrigal Pharmaceuticals $2,365.96 05/28/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244531
Principal investigator 1 Madrigal Pharmaceuticals $5,052.54 05/22/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244091
Principal investigator 1 Madrigal Pharmaceuticals $2,430.08 05/15/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243500
Principal investigator 1 Madrigal Pharmaceuticals $2,365.96 04/08/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241725
Principal investigator 1 Genentech, Inc. $8,428.00 04/04/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620105
Principal investigator 1 Bausch Health US, LLC $1,571.00 04/02/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842395
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763711
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763713
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763715
Principal investigator 1 Boehringer Ingelheim International GmbH $549.63 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763717
Principal investigator 1 Boehringer Ingelheim International GmbH $262.20 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763719
Principal investigator 1 Boehringer Ingelheim International GmbH $4.05 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763721
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763723
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763725
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763727
Principal investigator 1 Boehringer Ingelheim International GmbH $35.49 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763729
Principal investigator 1 Boehringer Ingelheim International GmbH $70.50 03/25/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763731
Principal investigator 1 Genentech, Inc. $4,816.00 03/21/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620092
Principal investigator 1 Boehringer Ingelheim International GmbH $1.20 03/14/2025 Non-covered Recipient Entity
Knowledge Research Center
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial No dispute reported 06/30/2026 1220763709
Principal investigator 1 Madrigal Pharmaceuticals $17,934.63 03/06/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240432
Principal investigator 1 Genentech, Inc. $7,884.00 02/26/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620100
Principal investigator 1 Genentech, Inc. $14,448.00 02/12/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620085
Principal investigator 1 Bausch Health US, LLC $377.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842352
Principal investigator 1 Bausch Health US, LLC $1,234.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842360
Principal investigator 1 Bausch Health US, LLC $1,358.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842364
Principal investigator 1 Bausch Health US, LLC $1,358.00 02/07/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842379
Principal investigator 1 Madrigal Pharmaceuticals $2,622.46 02/06/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239258
Principal investigator 1 Genentech, Inc. $25,120.00 02/05/2025 Non-covered Recipient Entity
KNOWLEDGE RESEARCH CENTER
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211620077
Principal investigator 1 Madrigal Pharmaceuticals $9,225.38 01/09/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238207
Principal investigator 1 Madrigal Pharmaceuticals $17,830.38 01/09/2025 Non-covered Recipient Entity
KNOWLEGE RESEARCH CENTER
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238211
Principal investigator 1 Bausch Health US, LLC $377.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842356
Principal investigator 1 Bausch Health US, LLC $1,639.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842367
Principal investigator 1 Bausch Health US, LLC $2,111.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842372
Principal investigator 1 Bausch Health US, LLC $2,111.00 01/08/2025 Non-covered Recipient Entity
Knowledge Research Center
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224842375